Welcome to our dedicated page for Harvard Apparatus Regenerative Technology SEC filings (Ticker: HRGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Harvard Apparatus Regenerative Technology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Harvard Apparatus Regenerative Technology's regulatory disclosures and financial reporting.
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors for a private placement of its common stock. The investors agreed to buy an aggregate of 411,765 shares of common stock at a purchase price of $1.70 per share, for an aggregate purchase price of approximately $0.7 million.
The shares were sold in a private transaction relying on exemptions from Securities Act registration, including Section 4(a)(2) for transactions not involving a public offering and Rule 506 for sales to an accredited investor, as well as similar state law exemptions. The Purchase Agreements contain customary representations, warranties, and covenants, and a form of the agreement is filed as an exhibit to the report.
Harvard Apparatus Regenerative Technology, Inc. reported an insider share purchase by its CEO. The company’s Chief Executive Officer and Director, based on this filing, bought 3,000 shares of common stock on 11/25/2025 in an open-market transaction coded “P” for a purchase. The weighted average purchase price reported was $1.70 per share, reflecting multiple trades between November 25 and November 26. Following this transaction, the reporting person beneficially owned 280,575 shares of Harvard Apparatus Regenerative Technology common stock held directly.
Harvard Apparatus Regenerative Technology (HRGN) filed its Q3 2025 10‑Q, reporting higher consumer health sales on a small base and continued operating losses, alongside a going concern warning. Q3 product revenue was $123,000 (vs. $59,000 a year ago), and the net loss was $1.7 million (vs. $1.9 million). For the first nine months, revenue reached $485,000 (vs. $172,000), while the net loss narrowed to $5.2 million (vs. $6.4 million), helped by lower selling, marketing, and G&A expenses.
Cash and equivalents were $1.3 million at September 30, 2025. Management states these funds are expected to support operations into the fourth quarter of 2025, raising substantial doubt about the company’s ability to continue as a going concern. The company completed a private placement on July 11, 2025, issuing 1,250,000 shares for gross proceeds of $2.0 million.
Deferred revenue was $128,000, and warrants outstanding totaled 898,622 with a weighted‑average exercise price of $5.33. 17,168,979 common shares were outstanding as of November 3, 2025.
He Junli, who serves as Chief Executive Officer and a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), purchased 11,225 shares of HRGN common stock in transactions executed between September 2, 2025 and September 22, 2025 at a weighted average price of $1.85 per share. Following these purchases the reporting person beneficially owned 277,275 shares. The Form 4 was signed by a power of attorney on September 24, 2025. The filing discloses no derivative transactions and notes the weighted average price reflects multiple trades; the reporting person will supply transaction-level price details on request.